Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
around 1,100 employees make essential contributions to the well-being of society for a future worth living. Empa is a research institution of the ETH Domain. Empa’s Laboratory Materials for Energy
-
Fribourg campus, with access to EPFL facilities and research infrastructure in both Fribourg and Lausanne. Additional information For more information about HOBEL: https://www.epfl.ch/labs/hobel/ For more
-
motivation are important assets. Fluency in English is essential. We offer A stimulating and international working environment Competitive salary and excellent working conditions – more information can be
-
-invasive targeted drug delivery to the brain. Our laboratory recently developed a novel focused ultrasound-mediated targeted drug delivery platform, published in Nature Communications (https://www.nature.com
-
make essential contributions to the well-being of society for a future worth living. Empa is a research institution of the ETH Domain. Empa’s Centre for X-ray Analytics develops X-ray analytical and
-
: https://www.epfl.ch/labs/hobel/ For more information about Prof. Dusan Licina: https://people.epfl.ch/dusan.licina For more information about EPFL: https://www.epfl.ch/en/ For more information about Smart
-
, cell biology and gas-exchange physiology. Within the research unit “Cereal Stem Cell Systems - RU52350; https://cerealstemcells.de ”, we are recruiting a Postdoc to investigate how grass leaves spatially
-
the earth sciences. NCCR Genesis does not aim to provide answers in all fields, but to drive innovative research and achieve decisive progress. Details on NCCR Genesis are available on its website https
-
sophisticated laser systems and regard instrumentation development as an essential part of outstanding experimental physics rather than merely a prerequisite for data acquisition Because many of the investigated
-
protocols. In close collaboration with the lab of George Coukos (https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs